{
  "patient_id": "MBC_005",
  "subtype": "TNBC",
  "biomarker_summary": {
    "ER": "negative",
    "PgR": "negative",
    "HER2": "negative",
    "PIK3CA": "wild_type",
    "BRCA1": "wild_type",
    "BRCA2": "wild_type",
    "PALB2": "wild_type",
    "MSI": "high",
    "TMB": 15.3
  },
  "treatment_history_summary": "2 prior line(s), last: sacituzumab govitecan",
  "recommendations": [
    {
      "treatment": "Sacituzumab Govitecan",
      "evidence_level": "I",
      "recommendation_strength": "Strong",
      "node_path": "Metastatic Breast Cancer Treatment Decision (ESMO 2021/24) -> Initial Biopsy, Biomarker & Staging Assessment (updated) -> Breast Cancer Subtype Classification -> Triple\u00e2\u20ac\u2018Negative Breast Cancer (TNBC) -> TNBC Second\u00e2\u20ac\u2018line (requires prior progression)",
      "rationale": "Patient has TNBC metastatic breast cancer. Recommended after progression on 2 prior line(s).",
      "keywords": [
        "Trop-2",
        "systemic therapy",
        "ADC",
        "metastatic breast cancer",
        "antibody drug conjugate",
        "sacituzumab govitecan"
      ]
    },
    {
      "treatment": "Standard single\u00e2\u20ac\u2018agent chemo",
      "evidence_level": "I",
      "recommendation_strength": "Moderate",
      "node_path": "Metastatic Breast Cancer Treatment Decision (ESMO 2021/24) -> Initial Biopsy, Biomarker & Staging Assessment (updated) -> Breast Cancer Subtype Classification -> Triple\u00e2\u20ac\u2018Negative Breast Cancer (TNBC) -> TNBC Second\u00e2\u20ac\u2018line (requires prior progression)",
      "rationale": "Patient has TNBC metastatic breast cancer. Recommended after progression on 2 prior line(s).",
      "keywords": [
        "systemic therapy",
        "metastatic breast cancer"
      ]
    },
    {
      "treatment": "Pembrolizumab (tumour\u00e2\u20ac\u2018agnostic)",
      "evidence_level": "II",
      "recommendation_strength": "Moderate",
      "node_path": "Metastatic Breast Cancer Treatment Decision (ESMO 2021/24) -> Initial Biopsy, Biomarker & Staging Assessment (updated) -> Tumour\u00e2\u20ac\u2018agnostic Targeted Therapy -> MSI\u00e2\u20ac\u2018High / dMMR",
      "rationale": "Patient has TNBC metastatic breast cancer. MSI-high tumor supports immunotherapy with pembrolizumab. Recommended after progression on 2 prior line(s).",
      "keywords": [
        "immunotherapy",
        "checkpoint inhibitor",
        "pembrolizumab",
        "metastatic breast cancer",
        "PD-1 inhibitor",
        "systemic therapy"
      ]
    },
    {
      "treatment": "Pembrolizumab (TMB\u00e2\u20ac\u2018high)",
      "evidence_level": "III",
      "recommendation_strength": "Weak",
      "node_path": "Metastatic Breast Cancer Treatment Decision (ESMO 2021/24) -> Initial Biopsy, Biomarker & Staging Assessment (updated) -> Tumour\u00e2\u20ac\u2018agnostic Targeted Therapy -> High Tumour Mutation Burden",
      "rationale": "Patient has TNBC metastatic breast cancer. MSI-high tumor supports immunotherapy with pembrolizumab. Recommended after progression on 2 prior line(s).",
      "keywords": [
        "immunotherapy",
        "checkpoint inhibitor",
        "pembrolizumab",
        "metastatic breast cancer",
        "PD-1 inhibitor",
        "systemic therapy"
      ]
    }
  ],
  "total_recommendations": 4
}